On a somewhat parallel note, Covid trial data is c
Post# of 148174
The long term prospects and myriad of likely clinical applications remain unchanged, IMO.
Whether leronlimab is authorized under EUA or an unlikely approval will be mostly immaterial to stock price and Covid patients needing it.
If trials meet endpoints with significance and no EUA, you can sign me up for the march on Washington.